Assessing Investigational CT1812’s Impact on Tau, Amyloid, and Neurodegeneration: Mary Hamby, PhD
April 3rd 2025The vice president of research at Cognition Therapeutics gave clinical insight on several new analyses covering CT1812, an orally delivered small molecule oligomer antagonist, in patients with early-stage Alzheimer disease. [WATCH TIME: 5 minutes]